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Introduction: The benzothiadiazines and high ceiling diuretics (hydrochloro-
thiazide, hydroflumethiazide, quinethazone, metolazone, chlorthalidone,
indapamide, furosemide and bumetanide) contain primary sulfamoyl moieties
acting as zinc-binding groups in the metalloenzyme carbonic anhydrase (CA,
EC 4.2.1.1). These drugs are widely used clinically and were recently shown to
weakly inhibit isoforms CA I and II, but to possess stronger activity against
isoforms involved in other important pathologies, for example, obesity, cancer,
epilepsy and hypertension.
Areas covered: The class of clinically used diuretics, with CA inhibitory proper-
ties, is the main topic of the review. A patent literature review covering the
period from 2005 to 2013 is presented.
Expert opinion: This section presents an overview of the patent literature in
the sulfonamide diuretic field. Most of the patents deal with the combination
of diuretic sulfonamide CA inhibitors with other agents useful in the manage-
ment of cardiovascular diseases and obesity. Such combinations exert a better
therapeutic activity compared to similar diuretics that do not inhibit CAs, rais-
ing the question of the polypharmacological and drug repositioning effects
of these old drugs. These effects seem to be due to the potent inhibition of
such drugs against CA isoforms present in kidneys and blood vessels, which
explain both the blood pressure lowering effects as well as organ-protective
activity of the drugs. An explanation of these data is provided by the fact that
inhibition of the renal CAs leads to a large increase of the nitrite excretion in
urine, suggesting that renal CAs are involved in nitrite reabsorption in
humans. Important lessons for the drug design of sulfonamide CA inhibitors
(CAIs) can be drawn from these data.
Keywords: carbonic anhydrase inhibitor, chlorthalidone, diuretic, furosemide and bumetanide,
hydrochlorothiazide, hydroflumethiazide, indapamide, metolazone, quinethazone, sulfonamide
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1. Introduction
A number of 16 different a-carbonic anhydrase (CA, EC 4.2.1.1) isoforms have
been described so far in mammals [1-5]. They catalyze the interconversion between
CO2, bicarbonate and protons, generating thus two of the ions (HCO3
-- and H+)
critical for pH regulation and many other physiological processes [6,7]:
CO +H O HCO +H2 2 3
- +
⇔
The human (h) CA isoforms possess a different catalytic activity, subcellular locali-
zation, tissue distribution and susceptibility to be inhibited by sulfonamides,
the main class of CA inhibitors (CAIs) [1-5,7,8]. There are several cytosolic forms
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(CA I--III, CA VII and CA XIII [6-10] as well as the acatalytic
CA VIII, X and XI [9]), five membrane-bound isozymes (CA
IV, CA IX, CA XII, CA XIV and CA XV), two mitochondrial
forms (CA VA and VB [11-15]), as well as one secreted CA iso-
zyme, CA VI [2,3]. CO2, bicarbonate and the protons gener-
ated in the CA-catalyzed reaction are involved in crucial
physiological processes connected with respiration and trans-
port of CO2/bicarbonate between metabolizing tissues and
lungs, pH and CO2 homeostasis, electrolyte secretion in a
variety of tissues/organs, biosynthetic reactions (such as gluco-
neogenesis, lipogenesis and ureagenesis), bone resorption,
calcification, tumorigenicity and many other physiological/
pathological processes [1,11-20].
2. Role of CAs in the kidney
Carbonic anhydrases (CAs) are highly abundant in the kid-
neys (a total concentration of about 8 -- 10 µM has been
estimated for this organ), and many isoforms have been
shown to be present in various tissues of this organ [21-25]. In
humans the CA isoforms present in kidneys are CA II, IV,
VB, IX, XII and XIV and they play a crucial function in at
least three physiological processes: i) the acid--base balance
homeostasis (by secreting and excreting protons, due to the
CO2 hydration reaction catalysed by these enzymes); ii) the
bicarbonate reabsorption processes and iii) the renal NH4
+
output [25-29]. These important functions are well localized
in the different segments of the nephron: bicarbonate reab-
sorption occurs in the proximal tubule, whereas urinary acid-
ification and NH4
+ output occur in the distal tubule and
collecting duct [25-29].
Carbonic anhydrase localization in the kidneys has been
extensively studied by histochemistry and immunohisto-
chemistry [21,25,30-32]. Of the catalytically active CA isozymes, at
least four (CA II, IV, XII, and XIV) were shown to be present
in the epithelial cells of renal tubules [30-35]. In the intercalated
cells of the late distal tubule, the collecting tubule and the collect-
ing duct, high levels of CA II have been reported [25,30-35]. The
CA II-positive segments along the mouse nephron and collecting
ducts include the proximal convoluted (S1 segment) and straight
tubules (S2 -- S3 segments), the descending thin limb of Henle,
the thick ascending limb of Henle, the distal convoluted tubule
and the intercalated and principal cells of the collecting
ducts [25,30-35]. On the basis of the distribution pattern described
above, it is obvious that CA II is widely expressed in the kidney
where it plays a key role in renal functions. Indeed, such a fun-
damental role of CA II in renal physiology was documented by
Sly et al. [36] who reported renal tubular acidosis (as well as brain
calcification and osteopetrosis) in patients with CA II-deficiency
syndrome [37]. The membrane-associated isoforms CA IV, IX,
XII and XIV are also present in various tissues of the kidneys:
CA IV seems to be ubiquitous in this organ [37], whereas CA
XII is expressed at the basolateral plasma membrane of the epi-
thelial cells in the thick ascending limb of Henle and distal con-
voluted tubules, and in the principal cells of the collecting
ducts [38]. CA XIV was found to be highly expressed in some seg-
ments of rodent nephron [24]. Strong signal was found in apical
plasma membranes of the S1 and S2 segments of the proximal
tubules, and weaker staining in the basolateral membranes as
well as in the initial portion of the thin descending limb of
Henle [24]. The positive staining in the proximal tubules sug-
gested that CA XIV might also function in urinary acidification
together with other isoforms present in this organ, that is, CA II,
IV, XII and so on. Finally, CA IX is highly overexpressed in renal
tumors [39-41]. A substantial amount of the renal physiology has
been understood in detail by inhibiting CAs present in this organ
by using sulfonamide CAIs [14,27,42,43].
3. Sulfonamide CAIs with diuretic action
Sulfonamides possessing the free SO2NH2 moiety act as
potent inhibitors of the CAs and bind in the deprotonated
form (as sulfonamidate anions) to the Zn(II) ion from the
enzyme active site, thus impairing the catalytic cycle [1-4,44-46].
Many such compounds have been in clinical use for decades
as antiglaucoma and diuretic agents [1-4,44-46], whereas a large
number of recent patents deal with the development of
Article highlights.
. Many of the clinically used diuretics, such as
hydrochlorothiazide, hydroflumethiazide, quinethazone,
metholazone, chlorthalidone, indapamide, furosemide
and bumetanide contain primary sulfamoyl moieties and
inhibit CA isoforms from the kidneys and other organs.
. The CAIs clinically used, such as acetazolamide,
methazolamide, ethoxzolamide and dichlorophenamide
have different inhibition profiles compared to the
thiazide- and high-ceiling diuretics incorporating SO2NH2
groups.
. A beneficial effect of indapamide/chlorthalidone/
hydrochlorothiazide for the treatment of patients with
hypertension and type 2 diabetes was observed,
thought to be due to the potent inhibition of these
drugs against CA isoforms present in kidneys and blood
vessels, leading to blood pressure lowering effects as
well as organ-protective activity of the drugs.
. Such polypharmacological/drug repositioning effects
may be useful in therapy and in the drug design of
sulfonamides possessing various biological activities
correlated to the CA inhibition (antiobesity, antiepileptic
and anticancer activity).
. There is a stringent need for new diuretic drugs to treat
edema, hypertension, obesity and cardiovascular
morbidities ensued by such conditions, since no new
sulfonamides with such effects were launched clinically
for a long period, although several recent patents report
interesting furosemide derivatives.
. Most of the analyzed patents report the combination
therapy of these drugs with other agents, mainly for the
management of cardiovascular diseases.
This box summarizes key points contained in the article.
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sulfonamide CAIs for a range of applications, mainly as
antitumor agents or diagnostic tools [16-20,47-55].
5-Acetamido-1,3,4-thiadiazole-2-sulfonamide, or acetazol-
amide 1, was the first CAI to be used clinically (Figure 1) [14].
Acetazolamide is a potent but promiscuous inhibitor against
most CA isoforms from mammals, but was the first non-
mercurial diuretic to be used clinically, starting with 1956 [14].
Acetazolamide represents the prototype of a class of pharmaco-
logical agents with apparently limited therapeutic usefulness
nowadays, but played a major role in the development of
fundamental renal physiology and pharmacology, as well as in
the design of many of the presently widely used diuretic agents,
such as thiazide and high ceiling diuretics, among others [1-4,56-60].
Following the administration of a CAI, such as acetazolamide 1,
the urine volume promptly increases, and its normally acidic pH
(of 6) becomes alkaline (around 8.2) [14]. An increased amount
of bicarbonate is thus eliminated into the urine (120 times
higher than the amount eliminated normally), together with
Na+ and K+ as accompanying cations, whereas the amount of
chloride excreted is diminished [14]. The increased alkalinity of
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Figure 1. The classical carbonic anhydrase inhibitors (CAIs) 1 -- 4, the orphan drug benzolamide 5 and the diuretics
incorporating sulfonamide groups and possessing CA inhibitory properties 6 -- 12.
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the urine is accompanied by a decrease in the excretion of titrat-
able acid and ammonia, and in consequence by metabolic acido-
sis [14,56]. This sequence of events is due to the inhibition of the
various CA isozymes in the proximal tubule (see the preceding
section), which leads to inhibition of H+ secretion by this seg-
ment of the nephron [14]. Inhibition of both cytosolic (CA II)
as well as membrane-bound (CA IV, XII and CA XIV)
enzymes seems to be involved in the diuretic effects of the
sulfonamides [1-4,14,56-60]. Inhibition of such CAs decreases
the availability of protons for the Na+ -- H+ antiporter, which
maintains a low proton concentration in the cell. The net
effect of these processes is the transport of sodium bicarbonate
from the tubular lumen to the interstitial space, followed by
movement of the isotonically obligated water and whence aug-
mented diuresis [4,14,56-60]. Carbonic anhydrase inhibitors also
increase phosphate excretion (by an unknown mechanism)
but have little or no effect on the excretion of calcium or
magnesium ions [4,14,56-60].
Acetazolamide 1 and structurally related sulfonamides
(Figure 1), such as methazolamide 2, ethoxzolamide 3 and
dichlorophenamide 4 were and are still used for the treatment
of edema due to congestive heart failure, and for drug-
induced edema, in addition to their applications as antiglau-
coma agents [4,14,56-60]. However, these systemic CAIs
generally produce many undesired side effects due to the
inhibition of CAs present in other organs than the kidneys.
The structurally related compound to acetazolamide, benzola-
mide 5, with an acidic pKa of 3.2 for the secondary sulfon-
amide group is completely ionized at the physiological pH,
as sulfonamidate anion [27,61]. Its renal effect on bicarbonate
excretion is around 10 times as potent as that of acetazol-
amide, the drug being maximally active at doses of 1 mg/kg,
and being actively and rapidly accumulated in the kidney, but
its plasma half-life is of only 20 min. All these facts make
benzolamide a renal specific CAI, but the compound remains
an orphan drug and has not been developed for wide clinical
use, due to its inappropriate pharmacokinetics, although some
anecdotal reports indicate that it might be beneficial for
patients suffering from chronic obstructive lung disease [27,61].
With all these limitations, acetazolamide, methazolamide,
ethoxzolamide and dichlorophenamide are still used for the
treatment of edema induced by drugs or congestive heart fail-
ure [62]. The same effects have been claimed in a recent patent
for furosemide, another CAI (see later in the text) [63]. These
inhibitors can cause, however, several undesired side effects,
such as metabolic acidosis, nephrolithiasis, CNS symptoms
and allergic reactions, which have limited their exploitation
in therapy [1,14,62]. The loss of bicarbonate and sodium is con-
sidered self-limited on continued administration of CAIs,
probably because the initial acidosis resulting from bicarbonate
loss activates bicarbonate reabsorption via CA-independent
mechanisms [14,25].
4. Second generation sulfonamide diuretics:
thiazides, indapamide, chlorthalidone,
furosemide, bumetanide and their congeners
The diuretics are widely employed drugs for controlling
hypertension [64-66]. They belong to several classes of pharma-
cological agents, but here we will discuss only the derivatives
incorporating a primary sulfonamide moiety in their mole-
cule. Indeed, by using acetazolamide 1 as a lead, a large
number of other quite successful sulfonamide diuretics
were developed in the 1960s and 1970s, such as the
Table 1. Inhibition data with some of the clinically used sulfonamides 1 -- 12 against isozymes I -- XV (the isoforms
CA VIII, X and XI are devoid of catalytic activity and probably do not bind sulfonamides as they do not contain
Zn(II) ions) [56-60].
Isozyme KI* (nM)*
1 2 3 4 5 6a 6b 7 8 9 10 11 12
hCA Iz 250 50 25 1200 15 328 2840 35000 54000 348 51900 62 4930
hCA IIz 12 14 8 38 9 290 435 1260 2000 138 2520 65 6980
hCA IIIz 2.105 7.105 1 106 6.8.105 1.4.105 7.9.105 8.7.105 nt 6.1. 105 1.1. 104 2.3.105 3.2 106 3.4 106
hCA IVz 74 6200 93 15000 nt 427 4780 nt 216 196 213 564 303
hCA VAz 63 65 25 630 37 4225 10200 nt 750 917 890 499 700
hCA VBz 54 62 19 21 34 603 429 nt 312 9 274 322 nt
hCA VIz 11 10 43 79 93 3655 8250 nt 1714 1347 1606 245 nt
hCA VIIz 2.5 2.1 0.8 26 0.45 5010 433 nt 2.1 2.8 0.23 513 nt
hCA IXz 25 27 34 50 49 367 412 nt 320 23 36 420 25.8
hCA XIIz 5.7 3.4 22 50 3.5 355 305 nt 5.4 4.5 10 261 21.1
mCA XIIIz 17 19 50 23 nt 3885 15400 nt 15 15 13 550 2570
hCA XIVz 41 43 25 345 33 4105 360 nt 5432 4130 4950 52 250
mCA XVz 72 65 58 95 70 135§ 141§ nt 79§ 143§ 234§ 176§ 431§
*h: Human; m: Murine isozyme; nt: Not tested, data not available.
zFrom [56-60].
§Data reported here for the first time (unpublished data from our laboratory).
F. Carta & C. T. Supuran
4 Expert Opin. Ther. Patents [Early Online]
Ex
pe
rt 
O
pi
n.
 T
he
r. 
Pa
te
nt
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
M
cM
as
te
r U
ni
ve
rs
ity
 o
n 
03
/1
8/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
benzothiadiazines 6 (hydrochlorothiazide 6a, hydroflume-
thiazide 6b and the like), quinethazone 7, metholazone 8,
chlorthalidone 9, indapamide 10, furosemide 11 and bume-
tanide 12 (Figure 1) [56-60]. Some of them are among the
most widely clinically used diuretics [67-70], alone or in
combination with other drugs such as b-adrenergic
receptor antagonists [71], cholesterol-lowering agents [72],
cardiac glycosides [73], inhibitors of neutral peptidase [74]
and so on. (only to mention several recent patents in
the field).
As mentioned above, these clinically used drugs 6 -- 12
possess the primary SO2NH2 moiety in their molecule, acting
as excellent zinc-binding groups for the metal ion present
within the CA active site, and normally associated with potent
CA inhibitory properties of the compounds incorporating
it [1,42,44-46]. However, till recently, the CA inhibitory properties
of these drugs were investigated only for one CA isozyme (i.e.,
CA II) that was presumed to be responsible for all the physio-
logical effects of the sulfonamide drugs in the 1960s and 1970s,
when these drugs were initially launched [56-60]. Only recently
the CA inhibition with these diuretics, against all mammalian
CA isoforms was thoroughly reinvestigated [56-60], offering
several interesting findings, which can lead to important poly-
pharmacological applications and drug repositioning of these
agents [75-77].
CA inhibition data with all sulfonamide diuretics (first and
second generation ones), of types 1 -- 12 is shown in Table 1.
Data of Table 1 show that similar to the clinically used/
orphan drug classical sulfonamide CAIs, that is, compounds
1 -- 5, the clinically used sulfonamide diuretics 6 -- 12 act as
inhibitors of all 13 investigated CA isozymes, but with an
inhibition profile quite different from that of inhibitors inves-
tigated earlier, and particularly different from that of the first
generation CAIs 1 -- 5. The following should be noted from
these inhibition data of all catalytically active mammalian
CA isoforms:
1) Hydrochlorothiazide 6a acted as a medium potency
inhibitor of isoforms hCA I, II, VB, IX and XII, with
inhibition constants in the range of 290 -- 603 nM,
the compound being a weaker inhibitor of isoforms
hCA VA, VI, VII, XIII and XIV (KIs in the range of
3.655 -- 5.010 µM) and an exceedingly weak one
against hCA III (KI of 0.79 mM). The best inhibited
isoform was mCA XV, with a KI of 135 nM;
2) Hydroflumethiazide 6b showed an inhibition profile
quite distinct from that of the closely structurally
related diuretic 6a, being a rather efficient inhibitor of
the following isoforms hCA II, VB, VII, IX, XII, XIV
and mCA XV, with inhibition constants in the range
of 141 -- 435 nM. It was a weaker inhibitor of hCA I,
IV and VI (KIs in the range of 2.84 -- 8.25 µM) and
showed very weak inhibition against isozymes hCA
III, VA and XIII (KIs of 10.2 -- 870 µM). It is thus
apparent that even small structural changes in the
benzothiadiazine scaffold, such as the substitution of
the chlorine atom in ortho to the sulfamoyl moiety by
a trifluoromethyl group, such as in the pair 6a/6b, has
dramatic consequences for the CA inhibitory properties
of the two compounds, basically against all investigated
CA isozymes (Table 1).
3) Quinethazone 7 is the only diuretic among compounds
1 -- 12 that is not approved for clinical use in Europe
(being approved in US), and this derivative was not
available for detailed investigations (its complete inhi-
bition data are also not available in the literature).
Some old literature data [14] showed it to be a very
weak hCA I and a modest hCA II inhibitor, with inhi-
bition constants in the range of 1.26 -- 35 µM (Table 1).
4) Metholazone 8 showed very weak hCA I and III inhib-
itory properties (KIs in the range of 54 -- 610 µM),
being a low micromolar inhibitor (thus, not a very
efficient one) of hCA II, VI and XIV, with inhibition
constants in the range of 1.714 -- 5.432 µM. However,
the drug was a medium potency inhibitor of isozymes
hCA IV, VA, VB and IX (KIs in the range of
216 -- 750 nM) and a very efficient one against hCA
VII, hCA XII, mCA XIII and mCA XV (KIs in the
range of 2.1 -- 79 nM).
5) Chlorthalidone 9 also showed a very interesting inhibi-
tion profile, acting as a weak hCA III inhibitor (with a
KI of 11 µM, this compound is one of the most effec-
tive hCA III inhibitors ever detected among all known
sulfonamides, [1], except trifluoromethanesulfonamide,
which has a KI of 0.9 µM), and a rather weak hCA
VI and hCA XIV inhibitor (KIs in the range of
1.347 -- 4.95 µM). Chlorthalidone was a moderate
hCA VA inhibitor (KI of 917 nM) and an effective,
or very effective inhibitor of the other mammalian
CA isozymes. Thus, the ubiquitous hCA I and II, as
well as hCA IV and mCA XV, showed inhibition con-
stants in the range of 138 -- 348 nM, but isoforms VB,
VII, IX, XII and XIII were inhibited in the low nano-
molar range (KIs in the range of 2.8 -- 23 nM). These
results showing 9 to be such a strong CAI against
many isoforms were rather unexpected, and consider-
ing the wide clinical use of the compound for the treat-
ment of hypertension [78,79], at least two issues can be
raised: first, is the inhibition of these CA isozymes
responsible for some of the therapeutic effects of the
drug (or for some side effects observed with it), and sec-
ond, can these observations be useful for the design of
CAIs with increased selectivity for some CA isoforms
or for envisaging novel therapeutic applications of the
drug (e.g., as an adjuvant to antitumor therapies, con-
sidering its strong inhibitory effects against the
tumor-associated CA isozymes IX and XII)? [1,40] We
shall try to reply to some of these questions after con-
sidering in detail the inhibition profile of the remaining
three drugs.
Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 -- 2013)
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6) Indapamide 10 acted as an inefficient CA I and III
inhibitor (KIs in the range of 51.9 -- 230 µM), was a
weak inhibitor of isoforms CA II, VA, VI, and XIV
(KIs in the range of 890 -- 4950 nM) but showed signi-
ficant inhibitory activity against CA IV and VB as well
as mCA XV (KIs in the range of 213 -- 274 nM). Inda-
pamide was an excellent inhibitor of CA VII, IX, XII
and mCA XIII, with inhibition constants in the low
nanomolar range (KIs in of 0.23 -- 36 nM). These
data are indeed remarkable, also considering the wide
use of the drug as a diuretic and its beneficial effects
in patients with type 2 diabetes mellitus, as recently
reported in several important clinical trials [67-69].
7) Furosemide 11 acted as a very weak hCA III inhibitor
(KI of 3200 µM), but showed moderate inhibitory
activity against many isoforms, such as CA IV, VA,
VB, VI, VII, IX, XII and mCA XIII/XV, with KIs in
the range of 176 -- 564 nM. The compound was on
the other hand a much better inhibitor of hCA I, II
and XIV, with KIs in the range of 52 -- 65 nM. Furose-
mide is probably one of the most investigated diuretics,
and a rather large number of patents deal with improv-
ing the bioavailability [80], combining it with other
agents [81], or synthesizing some of its analogs in which
the COOH moiety was transformed to esters or amides
for improving the penetration through membranes [82].
8) Bumetanide 12 was an extremely weak hCA III inhibi-
tor (KI of 3400 µM), similar to furosemide 11 with
which it is structurally related. However, bumetanide
was also a weak inhibitor of hCA I, II and XIII (KIs
in the range of 2570 -- 6980 nM), probably due to
the quite bulky phenoxy moiety in ortho to the sulfa-
moyl zinc-binding group. The compound showed bet-
ter inhibitory activity against isoforms CA IV, VA, XIV
and mCA XV (KIs in the range of 250 -- 700 nM) but
excellent inhibition of the tumor-associated isoforms
CA IX and XII (KIs in the range of 21.1 -- 25.8 nM,
that is,, the same order of magnitude as acetazolamide 1,
methazolamide 2 or ethoxzolamide 3). Thus, it may be
observed that bumetanide was an effective inhibitor of
only the tumor-associated isoforms CA IX and XII,
thus discriminating between these novel drug targets [40]
and other CA isoforms that should not be inhibited by
a cancer-specific CAI.
But what is important is the fact that the revisitation of
these old diuretics may have relevance for the drug design of
CAIs with diverse pharmacological applications [56-60]. There
are at least several aspects that need to be considered here
regarding the polypharmacology of these diuretic sulfona-
mides. First, these widely used drugs were considered to be
inactive as CAIs, due to the fact that they were launched in
a period when only CA II was well known (and considered
as responsible of all physiological effects of CAIs) [14]. How-
ever, the latest research in the field [56-60] led to the
observation reported here, that many of them do inhibit sub-
stantially several CA isoforms involved in crucial physiological
and pathological processes. In contrast to the classical CAIs of
type 1 -- 5 (generally low nanomolar CA II inhibitors), all
compounds 6 -- 12 (except furosemide 11) are much weaker
inhibitors of this isozyme, usually in the micromolar range.
Only furosemide 11 is a good CA II inhibitor among these
diuretics, with a KI of 65 nM, whereas all others showed KIs
in the range of 138 -- 6980 nM (Table 1). Again with the
exception of furosemide 11, the diuretics 6 -- 12 have low affin-
ity for CA I, the other isoform known when these drugs have
been discovered [14]. Data of Table 1 show that many of the
drugs 6 -- 12 appreciably inhibit CAs discovered after their
introduction in clinical use, with some low nanomolar (or
even sub-nanomolar) inhibitors against many of them. Exam-
ples of such situations are: metholazone 8 against CA VII, XII
and XIII; chlorthalidone 9 against CA VB, VII, IX, XII and
XIII; indapamide 10 against CA VII, IX, XII and XIII; furo-
semide 11 against CA I, II and XIV and bumetanide 12
against CA IX and XII among others (Table 1). As already
mentioned above, bumetanide 12 is a tumor-specific (target-
ing CA IX and XII) CAI, of equal potency to acetazolamide 1,
but without the promiscuity of acetazolamide, which is a
potent CAI against most mammalian isozymes. Indeed,
bumetanide is a weak inhibitor of all other isoforms except
CA IX and XII, which are overexpressed in tumors [40]. Inda-
pamide 10 and chlorthalidone 9 are also strong inhibitors of
the tumor-associated CAs, but they are also effective in inhib-
iting CA VII and XIII (Table 1). It is thus clear, that these old
drugs may indeed have newer applications in therapy or as
experimental agents, in situations which require the selective
inhibition of some CA isozymes, and which cannot be
obtained with the clinically used compounds of types 1 -- 4.
As far as we know, for the moment, no clinical trials are being
conducted to understand in detail the polypharmacological
aspects related to CA inhibition of these diuretics. This would
be favorable, as it would help the discovery of new agents (it is
worth mentioning that no diuretic possessing sulfonamide
moieties has been discovered for the last 40 years).
A second important aspect of the findings mentioned above
is whether some recent observations of clinical trials in which
such diuretic agents have been employed can be explained,
taking into consideration the CA inhibition, and how this is
reflected in drug design processes. Thus, a relevant question
arising when these diuretics are used is how the inhibitory
activities of compounds of type 6 -- 12 are reflected by the
pharmacological effects (or side effects profile) of these drugs?
It has recently been observed that indapamide 10 in combina-
tion with an ACE inhibitor (as diuretics) is highly beneficial
for the treatment of patients with hypertension and type 2
diabetes [68]. Treatment with indapamide was also shown to
lead to a significant decrease of plasma adiponectin concentra-
tion in patients with essential hypertension [69]. Adiponectin is
considered to participate in the pathogenesis of carbohydrate
metabolism disturbances often found in patients treated
F. Carta & C. T. Supuran
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with other thiazide-type diuretics [68,69]. On the other hand,
classical sulfonamide CAIs such as acetazolamide 1, methazo-
lamide 2 ethoxzolamide 3, and other compounds possessing
such properties, are known to induce vasodilation in a variety
of tissues and organs, including the kidneys, eye vasculature,
brain vessels and so on [83-85]. However, the exact mechanisms
by which they produce this beneficial effect for many pathol-
ogies (e.g., hypertension, glaucoma, diabetic retinopathy,
etc.), or the isoforms involved in it, are unknown for the
moment [86-89]. An attractive theory to explain this was
recently proposed by Tsikas’ group [90]. It is well known
that the kidney also plays an important role in nitrite/NO
homeostasis in the vasculature and that NO is one of the
main molecules involved in vasodilation [90,91]. The involve-
ment of renal CAs in endogenous nitrite reabsorption in the
proximal tubule was thus investigated [90]. The potent and
pan-CA inhibitor acetazolamide 1 was administered orally to
six healthy volunteers in the dosage of 5 mg/kg, and nitrite
was measured in spot urine samples before and after adminis-
tration. Acetazolamide abruptly increased the nitrite excretion
in urine, suggesting that renal CAs are involved in nitrite
reabsorption in humans. Additional in vitro experiments sup-
ported the hypothesis that nitrite reacts with CO2, analogous
to the reaction of peroxynitrite (ONOO-) with CO2, leading
to the formation of the acid-labile nitrito carbonate [ONOC
(O)O-] [90]. This reaction is hypothesized to be catalyzed by
CAs and that nitrito carbonate represents the nitrite form
that is actively transported into the kidney [90]. The signifi-
cance of nitrite reabsorption in the kidney and the underlying
mechanisms, notably a direct involvement of CAs in the reac-
tion between nitrite and CO2, remain to be elucidated at this
moment [90].
In line with these studies, a recent report also showed that
indapamide 10 has a protective role against ischemia-
induced injury and dysfunction of the blood--brain barrier,
probably due to its vasodilating effects [92]. An organ-
protective effect of indapamide in animal models of renal fail-
ure has also been reported, showing the drug to be beneficial
in preventing damage to the capillary structures, the endothe-
lium, and in reducing the hypertrophy of superficial glomer-
uli among others [93]. All these effects are probably mediated
by inhibition of CAs present in blood vessels or in the kid-
neys, but no specific pharmacological or biochemical studies
are available so far, except for these clinical observations men-
tioned here and the Tsikas paper discussed above [90]. The les-
son we learn from all these data is that probably many of the
recently reported beneficial clinical properties of indapa-
mide 10 are indeed due to its diuretic effects, but in conjunc-
tion with its strong inhibition of some CA isozymes (such as
CA IV, VB, VII, IX, XII and/or XIII) present in kidneys
and blood vessels. This hypothesis may explain both the blood
pressure lowering effects as well as organ-protective activity of
the drug. For medicinal chemists this means that it is proba-
bly possible to design sulfonamide CAIs possessing an inhibi-
tion profile similar to 10, but with a stronger activity against
the target isoform(s) involved in these pathologies. It is thus
not unexpected that a large number of recent patents claim
the combination therapy of hypertension and ensuing
cardiovascular comorbidities by using combination of these
diuretic agents (prevalently indapamide, chlorthalidone and
hydrochlorothiazide) with various other agents, such as
renin-angiotensin inhibitors, neutral endopeptidase inhibi-
tors, dronedarone, calcium channel blockers, adrenergic
agonists and so on [94-102].
It is interesting to note that some recent patents also claim
the possibility to treat hypertension and hyperuricemia
by combining diuretics of types 6 -- 12 with inhibitors of
the organic acid transporter isoform 4 (OA4), such as
2-(5-bromo-4-(cyclopropylnaphthalen-1-yl)4H-1,2,4-triazol-
3-ylthio) acetic acid [103], or that furosemide may act as a sub-
micromolar inhibitor of tautomerase from the parasite
Ancylostoma ceylanicum [104]. Undoubtedly, this class of ‘old’
drugs may still be able to afford interesting opportunities for
developing novel therapies based on such repositioning or
polypharmacological approaches.
5. Expert opinion
CAs are present in a multitude of isoforms in mammals, with
13 such catalytically active enzymes distributed in many tis-
sues. In kidneys CA II, IV, VB, IX (kidney tumors), XII,
and XIV are present in rather large amounts. These enzymes
play a fundamental role in the kidney physiology for the acid--
base balance homeostasis (by secreting and excreting protons,
due to the CO2 hydration reaction catalysed by these enzymes,
in the bicarbonate reabsorption processes and in the renal NH4
+
output). These important functions are well localized in the dif-
ferent segments of the nephron: bicarbonate reabsorption occurs
in the proximal tubule, whereas urinary acidification and NH4
+
output occur in the distal tubule and collecting duct, and made
renal CAs were thus investigated as drug targets, with the report
of the first CAI, acetazolamide, in the 1950s. This was followed
by the development of the thiazide and high-ceiling diuretics
that show such an effect also independently of their CA inhibitory
action [14]. However, the presence of free SO2NH2moieties in the
molecules of the benzothiadiazines 6 (hydrochlorothiazide 6a,
hydroflumethiazide 6b and the like), quinethazone 7, methola-
zone 8, chlorthalidone 9, indapamide 10, furosemide 11 and
bumetanide 12 induce strong CA inhibitory activities to these
drugs, which have been only recently re-evaluated against all the
mammalian active CA isoforms, that is,, CA I -- CA
XV [56-60]. These widely used drugs were in fact launched in a
period when only isoform CA II was known and considered
physiologically/pharmacologically relevant and thus no inhibi-
tion data against other CA isoforms were available till recently.
The new studies showed intriguing evidences regarding the CA
inhibitory properties of these drugs. Although acting as
moderate-weak inhibitors of CA II and CA I, all these drugs
considerably inhibited other CA isozymes known nowadays
to be involved in critical physiological processes. Some low
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nanomolar (or even sub-nanomolar) inhibitors against such iso-
forms were thus detected, such as metholazone against CA VII,
XII and XIII; chlorthalidone against CA VB, VII, IX, XII and
XIII; indapamide against CA VII, IX, XII and XIII; furosemide
against CA I, II and XIV and bumetanide against CA IX and
XII. The X-ray crystal structure of the adducts of CA II with
indapamide and chlorthalidone were also resolved [56-60],
explaining at molecular level the features associated with this
phenomenon, which may be useful for the drug design of novel
classes of CAIs.
It has also been proposed, based on these new data [56-60],
that the recently observed beneficial effect of indapamide/
chlorthalidone for the treatment of patients with hypertension
and type 2 diabetes may be due to the potent inhibition of the
two drugs against CA isoforms present in kidneys and blood
vessels, which would explain both the blood pressure lowering
effects as well as organ-protective activity of the drug. Indeed,
in a very important paper, Tsikas’ group explained that inhi-
bition of the renal CAs leads to a large increase in nitrite
excretion in urine, suggesting that renal CAs are involved in
nitrite reabsorption in humans [90]. Additional in vitro experi-
ments supported the hypothesis that nitrite reacts with CO2,
analogous to the reaction of peroxynitrite (ONOO-) with
CO2, leading to the formation of the acid-labile nitrito car-
bonate [ONOC(O)O-] [90]. Undoubtedly, such features are
probably also common to the other diuretic sulfonamides
that potently inhibit some renal CA isoforms, as discussed
above. It is thus not unexpected that a large number of recent
patents propose a repositioning of these old drugs for novel
biomedical applications, alone or in combination with other
agents. Important lessons for the drug design of novel CAIs,
based on the findings discussed in the review for the diuretic
sulfonamides, can also be drawn. In fact, by using such
drugs as lead molecules, a multitude of compounds possessing
interesting polypharmacological features may be obtained.
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